$150 million to scale DEXTER the surgical robot across the US
Distalmotion, the developer of surgical robot DEXTER which is designed to empower access to the benefits of robotic surgery in outpatient sites of care, has finalized its Series G financing round, raising $150M USD. The round was led by Revival Healthcare Capital and included inside investor participation.
DEXTER by Distalmotion is a soft tissue robotic surgery system designed to simplify operations to make the benefits of wristed robotics accessible in any operating room (OR). The surgical robot boasts a small, mobile footprint which allows integration into any size OR, without modifications, and easy maneuvering between rooms to optimize efficiency. The sterile console supports flexible surgical workflows, seamless transitions between laparoscopic and robotic techniques, and enhanced communication with OR teams. To date, Dexter has been successfully integrated into clinical practice across Europe and the US, with almost 3,000 patients treated.
Distalmotion has now closed a $150M series G funding round with Revival Healthcare Capital as lead investor, supported by existing investors. The funding will be used primarily to accelerate US commercial adoption of DEXTER as well as to support ongoing clinical and product development initiatives. A major focus of the US expansion continues to be the Ambulatory Surgery Center (ASC) market—one of the fastest-growing segments in surgical care, driven by the ongoing shift toward efficient, outpatient surgery.
“This funding marks another important milestone on our journey,” said Greg Roche, CEO of Distalmotion. “The continued commitment of our investors validates our vision to break down barriers to robotic access through simplified operations. As we enter our next phase of US market acceleration, ASCs represent a tremendous opportunity for DEXTER. The ongoing support from our investors reaffirms our roadmap, our mission, and the value DEXTER brings to minimally invasive surgery.”
Distalmotion strengthens Board
In conjunction with the financing, the company based at Biopôle in Lausanne, has named Chas McKhann as Executive Chairman of the Board of Directors. With more than 25 years in the MedTech and life sciences industries, McKhann brings a wealth of experience in scaling medical device companies, commercial acceleration, and guiding organizations through strategic growth. McKhann previously served as CEO of Apollo Endosurgery and then Silk Road Medical, two publicly traded medical device companies, where his leadership drove significant sales growth and ultimately resulted in successful exits. His appointment underscores Distalmotion’s commitment to establish a DEXTER leadership position in ASCs.
“I am thrilled to join the Distalmotion team,” said Mr. McKhann. “Distalmotion has reimagined how robotic surgery can be adopted across care settings because DEXTER delivers all the benefits of robotic surgery – dexterity, precision, and ergonomics – while also offering flexibility, efficiency, and value. With the recent FDA clearance in gynecology and release of DEXTER product enhancements, the company is poised to accelerate adoption in the US and globally at this pivotal stage in its growth trajectory.”
(Press release/RAN)